Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practicing in specific cardiology domains.
ECG and NT-proBNP & BNP can be used as a screening tool for PPCM. However, for the definitive diagnosis and monitoring of this disease echocardiography or MRI is necessary. Routine screening is not recommended at present. However, patients presenting with new onset fatigue, shortness of breath or other signs of heart failure should be screened.
Left bundle branch block during pregnancy as a sign of imminent peripartum cardiomyopathy
European Heart Journal 2010
Saida Labidi, Denise Hilfiker-Kleiner, and Gunnar Klein
Bromocriptine treatment associated with recovery from peripartum cardiomyopathy in siblings: two case reports
Journal of Medical Case Reports 2010
Gerd Peter Meyer, Saida Labidid, Edith Podewski, Karen Sliwa, Helmut Drexler, Denise Hilfiker-Kleiner
Recovery From Postpartum Cardiomyopathy in 2 Patients by Blocking Prolactin Release With Bromocriptine
Journal of the American College of Cardiology 2007
Denise Hilfiker-Kleiner, Gerd Peter Meyer, Elisabeth Schieffer, Britta Goldmann, Edith Podewski, Ingrid Struman, Philipp Fischer, Helmut Drexler
Medication: Standard therapy for heart failure including ACE-inhibitors and beta-blockers for at least 1 year. Thereafter, in patients with fully recovered function, controlled reduction of medication may be possible. However, no data on the outcome of patients stopping therapy is available.
Contraception: Further pregnancies should be avoided because of risk of recurrence. Some heart failure medications such as ACE-inhibitors and angiotensin receptor blockers may affect embryonic and foetal development.
Subsequent pregnancies: A general risk of relapse is observed. A 50% mortality in patients with an ejection fraction of less than 35% at onset of subsequent pregnancy has been reported.
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved